• About Us
    • Our Story
    • Values & Commitment
    • Our Process
    • Meet the Team
    • Our Partners
  • Compliance Services
    • Cell & Gene Therapy
    • Pharmaceutical Drugs
    • Medical Devices
    • FDA 483 / Warning Letter
    • US Agent & Official Correspondent
    • Audits
    • Compliance Without the Attorney Fees
    • Dietary Supplement
    • Facility Registration & Listing
    • FDA Compliance
    • Good Supply Practice
    • Modernization of Cosmetics Regulation Act
    • Quality Culture
    • Product Recalls
    • Quality Systems
    • Regulatory Affairs
    • Training
    • Virtual Quality Assurance
  • Expertise
    • Pharmaceutical
    • Medical Devices
    • Clinical
    • Biologics
  • Resources
    • Compliance Insight Blog
    • GXP Infusion
    • Quality Assurance Accreditation
    • Success Stories
    • Videos and Media
    • White Papers And Downloads
  • Search
  • Contact
Compliance Insight
Skip to content
  • About Us
    • Our Story
    • Values & Commitment
    • Our Process
    • Meet the Team
    • Our Partners
  • Compliance Services
    • Cell & Gene Therapy
    • Pharmaceutical Drugs
    • Medical Devices
    • FDA 483 / Warning Letter
    • US Agent & Official Correspondent
    • Audits
    • Compliance Without the Attorney Fees
    • Dietary Supplement
    • Facility Registration & Listing
    • FDA Compliance
    • Good Supply Practice
    • Modernization of Cosmetics Regulation Act
    • Quality Culture
    • Product Recalls
    • Quality Systems
    • Regulatory Affairs
    • Training
    • Virtual Quality Assurance
  • Expertise
    • Pharmaceutical
    • Medical Devices
    • Clinical
    • Biologics
  • Resources
    • Compliance Insight Blog
    • GXP Infusion
    • Quality Assurance Accreditation
    • Success Stories
    • Videos and Media
    • White Papers And Downloads
  • Search
  • Contact

FDA is announcing pilot program..

February 15, 2019by TLM

Share
  • Facebook
  • Twitter
  • LinkedIn
  • Email

 

FDA is announcing the opportunity for a limited number of applicants to participate in an Established Conditions Pilot Program to propose explicit established conditions (ECs) as part of an original new drug application (NDA), abbreviated new drug application (ANDA), biologics license application (BLA), or as a prior approval supplement (PAS) to any of these.

Please click on the link below to read the entire article posted on the Federal Register website.

https://www.federalregister.gov/documents/2019/02/15/2019-02364/established-conditions-pilot-program?utm_campaign=SBIA%3A%20Established%20Conditions%20Pilot%20Program&utm_medium=email&utm_source=Eloqua

Uncategorized

Be in Touch

info@compliance-insight.com
p. 513-860-3512

Corporate Headquarters

497 Circle Freeway Suite 230
Cincinnati, Ohio 45246

Business Hours

Monday – Friday
8:30am EST – 5:30pm EST

Social

© 2025 by Compliance Insight All Rights Reserved | Contact Us

Privacy Policy | Terms of Use | Use of Cookies